Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.78 |
| ▸ | PGK1 | P00558 | 3/20 | 0.65 |
| ▸ | PGK2 | P07205 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6327867 | 1.00 | ADORA2A (0.78) | ADORA2APGK1PGK2ADORA3ADORA1 | |
| SCHEMBL6327873 | 1.00 | ADORA2A (0.78) | ADORA2APGK1PGK2ADORA3ADORA1 | |
| SCHEMBL6913460 | 1.00 | ADORA2A (0.78) | ADORA2APGK1PGK2ADORA3ADORA1 | |
| SCHEMBL4560532 | 0.91 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4373572 | 0.91 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4373570 | 0.91 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6326890 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6052019 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6347121 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6347124 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209916-A1 | Combination therapies | PFIZER INC | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209916-A1 | Combination therapies | ADRA2C, ADRB2, ADRA2A | ADORA2A 10/4885PGK1 2235/4885PGK2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.